What Is Trulicity (Dulaglutide)?
Trulicity is the brand name for dulaglutide, a GLP-1 receptor agonist developed by Eli Lilly and approved by the FDA for the treatment of type 2 diabetes. Like its relatives semaglutide (Ozempic, Wegovy) and liraglutide (Victoza), dulaglutide mimics a naturally occurring gut hormone to lower blood sugar, reduce appetite, and — as clinical trials have demonstrated — protect the heart. Its once-weekly, single-use autoinjector pen was designed to make the injection as straightforward as possible for patients who are new to injectable medications.
The GLP-1 Mechanism: How Trulicity Lowers Blood Sugar
GLP-1 (glucagon-like peptide-1) is released from specialized cells in the small intestine when food is consumed. In people without diabetes, it has a fleeting half-life of a few minutes before being broken down by the enzyme DPP-4. Dulaglutide is an engineered molecule that binds GLP-1 receptors with high affinity and has a half-life of approximately 4.7 days — long enough for once-weekly dosing while maintaining stable blood levels throughout the week.
Once bound to GLP-1 receptors, dulaglutide activates several complementary pathways:
- Insulin secretion stimulation: Beta cells in the pancreas release insulin in a glucose-dependent manner — only when blood sugar is high — reducing the risk of hypoglycemia.
- Glucagon suppression: Alpha cell glucagon secretion is inhibited, reducing the liver's output of glucose between meals.
- Delayed gastric emptying: Food moves more slowly from the stomach, blunting post-meal glucose spikes and prolonging satiety.
- Central appetite effects: GLP-1 receptors in the brain's hypothalamus and brainstem modulate hunger and food intake, contributing to weight reduction.
FDA-Approved Use
Trulicity is FDA-approved to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is not approved for type 1 diabetes or for weight loss specifically (unlike Wegovy, which is semaglutide approved for obesity).
The REWIND Trial: Cardiovascular Outcomes Data
The REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial enrolled 9,901 adults with type 2 diabetes. Uniquely, over 68% of participants did not have established cardiovascular disease at baseline — they had only risk factors — making REWIND's population more representative of the broader type 2 diabetes population than earlier cardiovascular outcome trials. After a median follow-up of 5.4 years, dulaglutide reduced MACE (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 12% compared to placebo. Stroke reduction was a particularly notable finding from REWIND.
How Trulicity Compares to Ozempic and Other GLP-1 Agents
| Drug | Brand | Frequency | CV Outcome Trial | Weight Loss |
|---|---|---|---|---|
| Dulaglutide | Trulicity | Once weekly | REWIND (~12% MACE reduction) | Moderate |
| Semaglutide sc | Ozempic | Once weekly | SUSTAIN-6 (~26% MACE reduction) | Higher |
| Liraglutide | Victoza | Once daily | LEADER (~13% MACE reduction) | Moderate |
| Exenatide ER | Bydureon BCise | Once weekly | EXSCEL (neutral) | Modest |
In head-to-head trials comparing dulaglutide and semaglutide, semaglutide has generally demonstrated greater HbA1c reduction and weight loss. However, individual responses vary, and some patients find dulaglutide's tolerability profile or device design preferable. Both agents are reasonable choices for type 2 diabetes management in patients where cardiovascular protection is also a goal.
Side Effects
Gastrointestinal effects
Nausea, diarrhea, vomiting, and abdominal pain are the most common side effects of Trulicity, particularly during the first 4–8 weeks as the body adjusts to the medication. Eating smaller, lower-fat meals and remaining upright after eating can help manage these symptoms. Most patients find GI side effects diminish significantly after the initial adjustment period.
BLACK BOX WARNING — THYROID C-CELL TUMORS: Dulaglutide caused dose-dependent thyroid C-cell tumors in rodent studies. It is unknown whether this risk applies to humans. Trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Report any neck mass, difficulty swallowing, hoarseness, or shortness of breath to your provider promptly.
PANCREATITIS: Acute pancreatitis has been reported with GLP-1 receptor agonists. Discontinue Trulicity if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Symptoms include severe, persistent abdominal pain, often radiating to the back.
Weight effects
Trulicity produces modest to moderate weight reduction in most patients with type 2 diabetes, driven by the combination of delayed gastric emptying, appetite suppression, and reduced caloric intake. The degree of weight loss is generally less than that observed with semaglutide at its higher obesity-approved doses.
Injection site reactions
The single-use autoinjector is designed to minimize injection discomfort. Injection site reactions — redness, itching, or small lumps — can occur but are typically mild and resolve quickly. Rotating injection sites helps prevent localized tissue changes.
Want to compare Trulicity to Ozempic, Mounjaro, or other diabetes medications?
Compare MedicationsWho Should Not Use Trulicity
Trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. It is not approved for type 1 diabetes. Patients with a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), or known hypersensitivity to dulaglutide should discuss the risks with their healthcare provider before use.
Frequently Asked Questions
No. Trulicity (dulaglutide) and Ozempic (semaglutide) are different molecules in the same GLP-1 receptor agonist class. They share a similar mechanism and are both given as once-weekly injections for type 2 diabetes, but they differ in chemical structure, half-life, available doses, and clinical trial performance. Head-to-head trials have generally shown semaglutide to produce greater A1C reduction and weight loss. Both have cardiovascular outcome trial data supporting their use in high-risk patients.
Blood sugar lowering effects begin within the first week or two of starting Trulicity, but meaningful A1C reduction typically becomes apparent over 8–12 weeks. The full effect on A1C is usually assessed at 3–6 months. Appetite reduction and weight changes may also take several weeks to become noticeable. GI side effects tend to be most prominent in the first few weeks and generally improve as the body adapts.
Hair loss is not a commonly reported or well-established side effect of dulaglutide in clinical trials. However, some people losing weight rapidly on GLP-1 receptor agonists have reported a form of hair thinning called telogen effluvium — a stress response where hair follicles prematurely enter the resting phase due to rapid caloric restriction or significant physiological change. This type of hair loss is typically temporary and reverses as weight stabilizes. If you experience significant hair shedding, discuss it with your provider to evaluate for other contributing factors.